Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Prasugrel | |
| Synonyms |
PRASUGREL Prasugrel |
|
| Definitions |
An orally bioavailable thienopyridine, with antiplatelet activity. Upon oral administration, the active metabolite of prasugrel targets and irreversibly binds to the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor. This inhibits ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets and platelet adhesion and aggregation. This results in increased bleeding time. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C81566 |
|
| CAS_Registry |
150322-43-3
|
|
| Chemical_Formula |
C20H20FNO3S
|
|
| code |
C81566
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 |
|
| Contributing_Source |
CTRP FDA HemOnc
|
|
| DEFINITION |
An orally bioavailable thienopyridine, with antiplatelet activity. Upon oral administration, the active metabolite of prasugrel targets and irreversibly binds to the platelet receptor for adenosine diphosphate (ADP), thereby blocking the binding of ADP to its receptor. This inhibits ADP-mediated activation of the glycoprotein complex GPIIb/IIIa, fibrinogen binding to platelets and platelet adhesion and aggregation. This results in increased bleeding time.
|
|
| Display_Name |
Prasugrel
|
|
| FDA_UNII_Code |
34K66TBT99
|
|
| FULL_SYN |
PRASUGREL Prasugrel
|
|
| Has_Salt_Form | ||
| label |
Prasugrel
|
|
| Legacy Concept Name |
Prasugrel
|
|
| Preferred_Name |
Prasugrel
|
|
| prefixIRI |
Thesaurus:C81566
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C1620287
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |